Skip to main content
Erschienen in: Reactions Weekly 1/2017

01.02.2017 | Case report

Imatinib/nilotinib

Various toxicities: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (FDA MedWatch definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * requires intervention to prevent permanent impairment or damage
Literatur
Zurück zum Zitat Markarian M, et al. Pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia (CML): Reports collected by the French regional pharmacovigilance (PV) centers. Fundamental and Clinical Pharmacology 30 (Suppl. 1): 40 (plus poster) abstr. PM2-021, Apr 2016. Available from: URL: http://doi.org/10.1111/fcp.12189 [abstract] -France Markarian M, et al. Pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia (CML): Reports collected by the French regional pharmacovigilance (PV) centers. Fundamental and Clinical Pharmacology 30 (Suppl. 1): 40 (plus poster) abstr. PM2-021, Apr 2016. Available from: URL: http://​doi.​org/​10.​1111/​fcp.​12189 [abstract] -France
Metadaten
Titel
Imatinib/nilotinib
Various toxicities: 3 case reports
Publikationsdatum
01.02.2017
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2017
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-017-26755-5

Weitere Artikel der Ausgabe 1/2017

Reactions Weekly 1/2017 Zur Ausgabe

Case report

Pirfenidone

Case report

Pirfenidone

Case report

Mexiletine